I


Resource | v1 | created by semantic-scholar-bot |
Type Paper
Created 2015-01-01
Identifier DOI: 10.1515/9783111438443-001

Description

Ibandronate A bisphosphonate licensed for the treatment of postmenopausal osteoporosis. The drug can be administered orally or by slow intravenous injection. Orally, it is given before meals and washed down with a cup of water; afterwards, the patient must sit and not lie down for 30 min. The oral dose of 150 mg is given once a month, a regimen thought to improve compliance. It can also be administered by slow intravenous injection at a dose of 3 mg in 3ml every 3 months. This is particularly useful in patients with gastrointestinal intolerance of bisphosphonates.

Relations

Edit details Edit relations Attach new author Attach new topic Attach new resource
0.0 /10
useless alright awesome
from 0 reviews
Write comment Rate resource Tip: Rating is anonymous unless you also write a comment.
Resource level 0.0 /10
beginner intermediate advanced
Resource clarity 0.0 /10
hardly clear sometimes unclear perfectly clear
Reviewer's background 0.0 /10
none basics intermediate advanced expert
Comments 0
Currently, there aren't any comments.